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Background: Osteoarthritis of the shoulder or glenohumeral joint is a painful condition that
can be debilitating. Intra-articular injection with hyaluronic acid should be considered for
patients not responding adequately to physical therapy or anti-inﬂammatory medication.
Methods: This was a single-arm, open-label, prospective study of a single intra-articular
injection of NASHA (non-animal hyaluronic acid) in patients with symptomatic glenohum-
eral osteoarthritis. Patients were followed up for 26 weeks post-treatment, during which time
rescue medication with acetaminophen was permissible. The study objective was to demon-
strate that a single injection of NASHA is well tolerated with an over-6-month 25%
reduction in shoulder pain on movement, assessed using a 100-mm visual analog scale.
Results: Forty-one patients were enrolled, all of whom received study treatment. The mean
decrease in shoulder pain on movement score over the 6-month study period was −20.1 mm
(95% CI: −25.2, −15.0 mm), corresponding to a mean reduction of 29.5% (22.0, 37.0%).
Statistically signiﬁcant improvements were also observed in shoulder pain at night and
patient global assessment. There was no clear change over time in the percentage of patients
using rescue medication and mean weekly doses were below 3500 mg. Seventeen patients
(41.5%) experienced adverse events, all of which were mild or moderate. Two adverse events
(both shoulder pain) were deemed related to study treatment.
Conclusion: This study provides preliminary evidence that a single injection of NASHA
may be efﬁcacious over 6 months and well tolerated in patients with symptomatic gleno-
humeral osteoarthritis. Larger studies are needed for conﬁrmation.
Keywords: Durolane®, glenohumeral joint, non-animal hyaluronic acid, osteoarthritis,
shoulder, viscosupplementation
Background
In the normal shoulder or glenohumeral (GH) joint, smooth motion is facilitated by
cartilage, which surrounds the articular portion of the bones, and hyaluronic acid
within the synovial ﬂuid. With age and normal wear and tear, cartilage degenerates
and osteoarthritis (OA) can develop. The prevalence of GH-OA has not been
studied extensively, but it is known to increase with age and has been estimated
broadly as 4–26%.1 The features of GH-OA may include joint effusion, stiffness
that improves with re st, crepitus, decreased range of motion, joint space narrowing,
subchondral sclerosis and osteophyte formation.2
Some GH-OA patients not responding adequately to physical therapy or anti-
inﬂammatory medication may not wish to progress directly to surgery or there may
Correspondence: Andrew J Harrison
Bioventus Cooperatief UA, Taurusavenue
31, Hoofddorp, LS 2132, Netherlands
Tel +44796 621 7187
Email Andrew.Harrison@bioventusglobal.
com
Medical Devices: Evidence and Research Dovepress
open access to scientiﬁc and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Medical Devices: Evidence and Research 2019:12 227–234 227
DovePress © 2019 McKee et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
http://doi.org/10.2147/MDER.S189522
 
M
ed
ica
l D
ev
ice
s:
 E
vid
en
ce
 a
nd
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
0.
13
5.
11
8.
49
 o
n 
06
-A
ug
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
be clinical reasons for avoiding surgery. Under such cir-
cumstances, the patient has the option of intra-articular
injection with either a corticosteroid or hyaluronic acid
(HA). Numerous studies have reported that intra-articular
HA injection is well tolerated and can provide statistically
signiﬁcant reductions in pain.3–10 NASHA (non-animal
hyaluronic acid) is a biocompatible HA with a prolonged
intra-articular residence time that been used as a treatment
for knee and hip OA since 2001.11–16 In 2010, the
approved indications for NASHA in the EU were
expanded to include pain relief associated with OA in
joints of all sizes except for the temporomandibular and
facet joints.17
This study was performed to evaluate the efﬁcacy,
safety and tolerability of a single intra-articular injection
of NASHA for the relief of pain over 26 weeks in patients
with symptomatic GH-OA.
Methods
This single-arm, open-label study (Clinicaltrials.gov identi-
ﬁer NCT02610504) was performed prospectively at two
outpatient clinics in Canada. Approval was obtained from
St Michael’s Hospital Research Ethics Board (reference
number 14–325) before the study commenced and, because
GH-OA was not an approved indication for NASHA in
Canada at the time of the study, authorization from Health
Canada was required. All patients provided signed informed
consent before undergoing study procedures. The principles
of Good Clinical Practice and the Declaration of Helsinki
were adhered to throughout. As far as possible, this study
was conducted in accordance with the Consolidated
Standards of Reporting Trials (CONSORT) guidelines.18
Adults aged 19–85 years with a body mass index
≤35 kg/m2, and symptomatic GH-OA and radiographic evi-
dence of disease were eligible for inclusion in the study.
Radiographic examinations were performed by a radiologist
and reviewed by the relevant surgeon. The Kellgren–
Lawrence grading system was applied, and individuals
with mild to moderate disease (Kellgren–Lawrence grade
2–3) were selected for inclusion. At screening, pain was
assessed using the “shoulder pain on movement” (SPOM)
visual analog scale (VAS), with a range from zero (no pain)
to 100 mm (severe pain), and a score ≥50 mm was required
for study participation. In addition, patients had to have
experienced pain on at least 50% of the days during the
previous month. All study participants had failed conven-
tional therapy (non-steroidal anti-inﬂammatory drugs; one
or more intra-articular or peri-articular steroid injection;
and ≥1 month of physiotherapy) and, for the duration of
the study (including the week before administration of study
treatment), had to agree to cessation of analgesic treatment
apart from acetaminophen which was permitted as rescue
medication (except during the 24 hrs preceding each study
visit). Intra-articular or peri-articular injections apart from
the study intervention were also not permitted during the
study period. OA in the contralateral shoulder was permis-
sible provided that OA symptoms were greater in the study
shoulder. Exclusion criteria included signiﬁcant pain from
other joints or low back pain requiring chronic analgesic
therapy, the presence of any condition that could have con-
founded the assessment of pain/disability in the study
shoulder, and pathologies other than OA in the study
shoulder (range of motion <30% in any direction; clinically
apparent tense effusion, gross misalignment or instability,
acute fracture, severe loss of bone density, avascular necro-
sis or severe deformity). Individuals who had undergone
surgery in the study shoulder within the previous 12 months
received an intra-articular or peri-articular steroid injection
into the study shoulder within the previous 3 months or
received an intra-articular HA injection into the study joint
within the previous 9 months were also excluded.
Durolane® (NASHA non-animal hyaluronic acid;
Bioventus LLC, Durham, NC, USA; preﬁlled 3 mL syr-
inge; 20 mg/mL) was injected into the GH joint at the
baseline clinic visit. Each patient received a single injec-
tion into one shoulder (the “study joint”). 21/23
G needles of length 3.8–5.1 cm were used (needles not
provided in the product package). Application of a topical
anesthetic (eg, ethyl chloride or lidocaine spray) or sub-
cutaneous lidocaine and the use of image guidance were
permissible but not mandatory. All injections were per-
formed by a shoulder surgeon experienced in delivering
intra-articular injections into the GH joint. After the
injection procedure, patients were asked to remain at
the study site for 30 mins to monitor for adverse events
(AEs) and advised to rest the study joint for at least
24 hrs.
Follow-up visits were scheduled at 6, 12 and 26
weeks post-treatment, and a phone call was undertaken
at 18 weeks. Thus, with the exception of the 18-week
timepoint, all data were collected at the outpatient clinics
serving as the study centers. The primary efﬁcacy vari-
able was the SPOM VAS score. The secondary efﬁcacy
variables shoulder pain at night (SPAN) and patient
global assessment were measured using a 0–100 mm
VAS. In addition, the American shoulder and elbow
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surgeons (ASES) patient self-evaluation Shoulder Score
Index (SSI; score range 0–100) and rescue medication
consumption (mg/week) were assessed. Safety was mon-
itored by recording AEs (classiﬁed according to the
medical dictionary for regulatory activities [MedDRA]),
vital signs and physical examination results. Local
symptoms following intra-articular injection were antici-
pated and recognized as AEs only if they were worse
than symptoms occurring before the procedure or were
worse than typically expected for this type of treatment.
Signs and symptoms of GH-OA occurring after study
treatment were not considered as AEs if they were also
present before treatment, unless representing a clinically
signiﬁcant exacerbation of the disease or a recurrence
following initial recovery.
Statistical methods
Safety data were analyzed based on the safety set,
deﬁned as all patients who were exposed to the study
treatment. Efﬁcacy data were summarized using descrip-
tive statistics for the full analysis set, deﬁned as all
patients in the safety set who had at least one post-
treatment efﬁcacy assessment. For missing values, no
imputation was performed. A mixed effects repeated
measures (MERM) regression analysis was used for all
inferential statistics; enrolment site and visit week were
ﬁxed-effect covariates and patients were random effects.
Least square mean (LSMean) values were calculated for
speciﬁc time points and for estimates over the 26-week
study period; the latter were based on all post-treatment
assessments (ie, weeks 6, 12, 18 and 26). All MERM
LSMean estimates include and are adjusted for the
assessments of patients who withdrew from the study
early. SAS version 9.4 or higher was used for all statis-
tical analyses.
The success criterion for the study (the primary out-
come) was a 25% reduction from baseline in the SPOM
VAS score over the 26-week study period, with the
F-statistic for change from baseline achieving the 0.05
type I error level. A minimum sample size of 29 was
determined for detecting a reduction in mean SPOM VAS
score of 15 mm (25% reduction from a baseline mean of
60 mm) with 80% power. This was based on a standard
deviation (SD) within each timepoint of 25 mm and
correlation between visits of 0.5. A minimum enrolment
of 36 patients was planned to allow the power of the
study to be maintained in case of a drop-out rate up
to 20%.
Data tables and listings related to the efﬁcacy and
safety results of this study are available upon request
from the study sponsor.
Results
Study participants
A total of 41 patients were enrolled into the study, all of
whom received study treatment. The date of ﬁrst enroll-
ment was 8th April 2015, and the last patient’s ﬁnal
follow-up visit was on 23rd May 2017. One patient
received a subcutaneous injection of celestone for OA
of the thumb at the screening visit and was discontinued
from the study on Day 1, before any post-baseline
efﬁcacy assessments had been made. Consequently,
there were 41 patients in the safety set, of whom 40
were included in the full analysis set. Sixteen full ana-
lysis set patients discontinued from the study before
Week 26: ﬁve underwent shoulder replacement surgery,
four withdrew consent, three were lost to follow-up, two
had protocol violations and two discontinued according
to physician decision. Therefore, 24 patients were fol-
lowed to the end of the study.
The mean age at enrolment was 65.4 years, and the
majority of the population (70.7%) were male (Table 1).
Twenty-ﬁve patients (61.0%) had a body mass index of
25.0–29.9 kg/m2 and were classiﬁed as overweight, while
nine (22.0%) had a body mass index ≥30.0 kg/m2 and were
classiﬁed as obese. The study joint was the left shoulder in 20
patients (48.8%) and the right shoulder in the remaining 21
(51.2%). Shoulder OAwas diagnosed during the previous 6
months in 26 patients (63.4%). The injection procedure was
performed without anesthetic in 29 patients (70.7%), and all
treatments were administered without image guidance. No
aspirations were performed, and the entire volume (3 mL)
was given for all injections. An 18-22G needle was used for
28 of the 41 injections (68.3%) and a 22-25G needle was
used for the other 13 (31.7%).
Table 1 Patient demographics and baseline characteristics (safety
set, N=41)
Characteristic Mean (SD) or n (%)
Age (years) 65.4 (9.5)
Male gender 29 (70.7%)
Body weight (kg) 83.4 (17.7)
Body mass index (kg/m2) 28.4 (4.8)
Dovepress McKee et al
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Primary efﬁcacy analysis
The mean SPOMVAS score at each study timepoint is shown
in Figure 1. The decrease versus baseline in SPOMVAS score
was greatest atWeek 12 and exceeded 25% at every timepoint.
A similar pattern was observed with LSMean values, although
these data suggest slightly smaller improvements versus base-
line compared with the unadjusted means (Table 2). The
LSMean change from baseline in SPOM VAS score over the
whole 26-week study period was −20.1 mm (95% CI: −25.2,
−15.0 mm), corresponding to an LSMean percentage
reduction of 29.5% (22.0, 37.0%). The change from baseline
F-statistic was 8.97 (p<0.0001) and the t-statistic was −7.92
(p<0.0001), demonstrating that the treatment beneﬁt over the
study period was statistically signiﬁcant. Thus, the study suc-
cess criterion (SPOM VAS score ≥25% reduction from base-
line with F-statistic p≤0.05) was met.
Secondary efﬁcacy analyses
At all post-treatment timepoints, treatment with NASHA
produced improvements versus baseline in the SPAN VAS
90
80
70
60
50
40
30
20
M
ea
n 
± 
S
D
10
0
-10
-20 Baseline Week 6 Week 12 Week 18 Week 26
Mean SPOM VAS score
Mean decrease from baseline
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Figure 1 Shoulder pain on movement (SPOM) visual analog scale (VAS) results: mean score and mean percentage change from baseline. Error bars represent standard
deviation (SD).
Table 2 Primary and secondary efﬁcacy results in the full analysis set (N=40)
Variable Baseline
(n=40)
Week 6
(n=39)
Week 12
(n=30)
Week 18
(n=19)
Week 26
(n=24)
SPOM VAS score
- Mean (SD)
- LSMean (SE)
70.9 (13.7) 50.7 (24.6)
48.5 (3.4)
44.1 (26.0)
47.4 (3.2)
46.4 (27.9)
49.0 (3.4)
50.0 (26.8)
50.1 (3.4)
SPAN VAS score
- Mean (SD)
- LSMean (SE)
70.1 (20.5) 50.7 (26.4)
49.3 (4.1)
46.2 (27.8)
49.6 (3.9)
43.8 (23.9)
50.0 (3.7)
49.5 (31.8)
51.1 (3.9)
Patient global assessment VAS score
- Mean (SD)
- LSMean (SE)
40.7 (22.3) 55.1 (25.2)
58.9 (3.9)
60.2 (21.3)
59.4 (3.2)
68.6 (19.5)
61.2 (3.1)
53.3 (25.6)
57.8 (3.3)
ASES patient self-evaluation SSI score
- Mean (SD)
- LSMean (SE)
55.2 (19.2) 62.9 (20.9)
65.2 (3.7)
65.6 (14.9)
65.8 (3.2)
58.8 (14.0)
63.5 (3.1)
60.2 (19.9)
62.0 (3.0)
Use of rescue medication since the previous clinic visit
- number of patients, n/N (%)
- weekly dose [mg], mean (SD)*
5/32 (15.6)
6000 (NE)
19/39 (48.7)
3150 (4175)
12/32 (37.5)
1888 (1843)
12/25 (48.0)
1916 (1754)
9/23 (39.1)
3254 (2619)
Notes: *Not every patient who reported taking rescue medication reported the dose; at baseline, only one patient reported a dose.
Abbreviations: ASES, American shoulder and elbow surgeons; LSMean, least square mean; NE, not evaluable; SD, standard deviation; SE, standard error; SPAN, shoulder
pain at night; SPOM, shoulder pain on movement; SSI, shoulder score index; VAS, visual analog scale.
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score (Table 2). The LSMean change from baseline over
the 26-week study period was −16.7 mm (−23.7,
−9.7 mm), corresponding to an LSMean percentage
decrease of 16.6%. The change from baseline F-statistic
(7.66; p<0.0001) and the t-statistic (−4.78; p<0.0001) con-
ﬁrmed that the improvement in SPAN VAS score over the
whole study period was statistically signiﬁcant. The great-
est improvement in SPAN VAS unadjusted mean score
was observed at 18 weeks, while the SPAN adjusted
LSMean scores were stable at about 50 mm across all
visits post-baseline (ranging between 49.3 mm at Week 6
and 51.1 mm at Week 26).
Patient global assessment scores also improved after
study treatment, with scores higher than baseline at every
timepoint post-treatment (Table 2). For the whole period
of the study, the LSMean change from baseline over was
+9.80 mm (2.92, 16.68 mm), which corresponded to an
LSMean percentage change of +69.08%. The improve-
ment was statistically signiﬁcant, as shown by the
F-statistic (5.79; p=0.0006) and the t-statistic (2.85;
p=0.0061). The greatest improvement in patient global
assessment was evident at 18 weeks.
Patient numbers were reduced for analysis of ASES
SSI scores because if a patient failed to answer any one of
the 11 questions the score could not be calculated. Despite
this, a statistically signiﬁcant improvement was evident
over the 26-week study period, with an LSMean change
from baseline of 6.06 (1.51, 10.61), representing a 5.72%
increase. Statistical signiﬁcance was shown by the
F-statistic and the t-statistic (4.29, p=0.0084; 2.71,
p=0.0104, respectively). The ASES SSI score peaked at
12 weeks and an improvement versus baseline was appar-
ent at every timepoint, according to both LSMean and
unadjusted mean values.
There was no clear change over time in the percentage of
patients using rescue medication (ie, acetaminophen) since
the previous visit. The highest percentages were at 6 weeks
(48.7%) and 18 weeks (48.0%). The mean weekly doses post-
treatment were all below 3500 mg, corresponding to mean
daily doses less than 500 mg. Dose information was derived
from relatively reduced numbers of patients (one patient at
baseline, 7–10 patients at the post-treatment timepoints).
Safety
Seventeen out of 41 patients (41.5%) experienced AEs
during the study (Table 3). No AEs occurred during the
injection procedures. All AEs were mild or moderate in
intensity, and the most commonly reported ones were
headache, musculoskeletal pain and arthralgia. Two AEs
were adjudged to be related to the study treatment, both of
which were musculoskeletal pain (shoulder pain). There
were no serious adverse events or deaths during the study,
and no patients withdrew from the study due to an AE.
There were no cases of study joint inﬂammation and no
infections of the skin covering the study joint. Changes
from baseline in vital sign measurements were minimal,
and only one abnormality was found upon physical exam-
ination (sore feet, which was reported as an AE).
Discussion
This study represents the ﬁrst prospective assessment of
intra-articular NASHA for shoulder OA. The treatment
was well tolerated, and the primary efﬁcacy criterion
(SPOM VAS score ≥25% reduction from baseline) was
met. Clinically and statistically signiﬁcant improvements
in shoulder pain, both upon movement and at night, were
evident throughout the 6-month study period and these
were accompanied by improved patient global assessment
scores. The percentage of patients taking rescue acetami-
nophen did not show a tendency to change over time, and
the mean dose per day (<500 mg) was well below the
maximum allowed (4,000 mg).
The percentage decrease from baseline in the SPOM
VAS score of 29.5% (over the whole study period) is very
close to the decrease in pain deﬁned in the Initiative on
Methods, Measurement, and Pain Assessment in Clinical
Trials (IMMPACT) recommendations as “moderately
important” (30–49% decrease).19 Previous studies in knee
and hip OA have suggested how to interpret changes from
baseline in the Western Ontario & McMaster Universities
Osteoarthritis Index (WOMAC) pain VAS score. The abso-
lute change from baseline in our study (20.1 mm) was
similar to or above the minimum clinically important
improvement, and approximately double the minimum
Table 3 Adverse events occurring in more than one patient
(safety set, N=41)
Adverse event Number of patients
(%)
Any 17 (41.5)
Headache 6 (14.6)
Musculoskeletal pain 3 (7.3)
Arthralgia 3 (7.3)
Pain in extremity 2 (4.9)
Viral upper respiratory tract infection 2 (4.9)
Dovepress McKee et al
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clinically perceptible improvement.20,21 The assessment
method in our study (SPOM VAS score) was different
from the WOMAC method, but the comparisons suggest
that the improvement seen in our study was clinically
relevant.
Treatment-emergent AEs occurred in less than half of
patients and were mild or moderate in intensity. No serious
adverse events occurred during the study, there were only
two treatment-related adverse events, and no patients with-
drew from the study because of AEs. Therefore, there is no
suggestion of any safety concerns associated with NASHA
as a treatment for GH-OA.
The discontinuation rate in this study was higher than
anticipated, with 17/41 patients (41.5%) withdrawing
before 26 weeks. Despite the number of patients complet-
ing the study falling below 29, the minimum suggested by
the sample size calculation, the success criterion was still
met. This is attributable to the use of MERM methodol-
ogy, which uses the available data from all study partici-
pants (missing data were imputed by projected outcomes),
and the observed treatment effect being larger than that
assumed in the sample size calculation. Shoulder replace-
ment surgery was the primary reason for discontinuation in
ﬁve cases and a further six patients who discontinued were
on a waiting list for shoulder surgery. Although these 11
patients met the inclusion criteria, they should probably
not have been included in the study because of the exclu-
sion criterion “subjects not likely to avoid other therapies”
(there was always a risk that they could discontinue at any
time). A post-hoc analysis showed the percentage reduc-
tion from baseline in SPOM VAS score over 12 weeks was
38.8% in the 29 non-surgery patients within the full ana-
lysis set, compared with 19.2% in the 11 surgery patients.
These results suggest that patients undergoing or planning
shoulder surgery had GH-OA that was more advanced
than in the other study participants, and this would have
reduced the likelihood of an optimal response to viscosup-
plementation. This supposition is borne out by the adjusted
SPOM, SPAN and PGA LSMeans showing slightly
reduced improvements compared with the unadjusted
means. It is possible that the 11 surgery patients partici-
pated in the study as a personal bridging strategy to help
manage pain until the time of surgery.
Intra-articular HA has previously been shown to be
efﬁcacious in patients with GH-OA. The largest previous
study was randomized, double-blind and placebo-
controlled.3 A total of 660 patients were randomized to
receive 5 weekly injections: all sodium hyaluronate, three
sodium hyaluronate and two saline, or all saline. The
primary endpoint (shoulder pain at 13 weeks) did not
show a signiﬁcant beneﬁt with sodium hyaluronate.
However, there were trends in favor of active treatment
and signiﬁcant improvements versus placebo were
observed at Week 7 (all sodium hyaluronate), Week 17
(three and ﬁve sodium hyaluronate injections) and Week
26 (three sodium hyaluronate injections). In a second ran-
domized, placebo-controlled trial, 300 patients received
three, weekly injections of sodium hyaluronate or
placebo.5 There were no signiﬁcant overall between-
group differences in VAS pain score or Outcome
Measures in Rheumatoid Clinical Trials-Osteoarthritis
Research Society International (OMERACT-OARSI)
response rate, but signiﬁcant beneﬁts were observed with
sodium hyaluronate in a subgroup of patients without
concomitant pathologies. In both of these trials, AE rates
were similar with sodium hyaluronate and placebo, and
there were no serious treatment-related AEs. Three intra-
articular injections of HA with 15-day intervals, combined
with physiotherapy for 3 months, were compared with
physiotherapy only in a third randomized trial, involving
78 patients.4 Six months after treatment was started, the
Constant score was statistically signiﬁcantly higher in the
HA group versus physiotherapy only, indicating reduced
pain, and no AEs were reported.
A retrospective study compared GH-OA patients trea-
ted with three, weekly injections of either hylan G-F 20
(n=51) or a corticosteroid (n=33).6 Signiﬁcant beneﬁts
versus baseline were observed with sodium hyaluronate
at 1, 3 and 6 months, with respect to VAS pain score and
the Shoulder, Pain and Disability Index. Improvements
versus baseline were also seen in the corticosteroid
group, but only at 1 month post-treatment.
A number of single-arm, uncontrolled studies have also
been published. Two such studies were performed with
hylan G-F 20; one was a preliminary investigation of
three, weekly injections in 30 patients9 and the other was
a multicenter study in which 33 patients received a single
injection, with a second injection available after 1, 2 or 3
months.7 Signiﬁcant reductions in pain were reported in
both of these studies; the multicenter study showed mean
VAS pain score improving from 61 mm at baseline to
37 mm at 3 months. No serious or severe treatment-
related AEs were reported in either of these studies.
Three weekly injections of high molecular weight hyalur-
onan were assessed in a cohort of 27 patients.10 Signiﬁcant
improvements in VAS pain score were evident over 26
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weeks and an OMERACT-OARSI response rate of 78%
was reported. There were no treatment-related AEs. In
a more recent study, HYADD4-G was administered as
two injections, 1 week apart, and patients were followed
up for 26 weeks.8 In the 41 study participants, SPOM VAS
score improved from 66 mm at baseline to 38 mm at 6
months, with a greater improvement over the ﬁrst 13
weeks than over the second 13 weeks post-treatment.
There were no serious AEs.
NASHA was the ﬁrst HA product to be administered
routinely as a single injection, instead of multiple injec-
tions. It has a prolonged intra-articular residence time
because a unique molecular cross-linking process is under-
taken during manufacture.22 The efﬁcacy of one NASHA
injection appears to be broadly similar to that achieved
with multiple injections of other HA products.16 Treatment
with a single injection requires less health care profes-
sional time than multiple injections, lowering this dimen-
sion of treatment cost, and patients are likely to prefer
having to undergo only one injection.
Treatment guidelines for GH-OA are lacking, but a UK
patient care pathway was published in 2016.1 This pub-
lication includes consideration of a broad range of treat-
ment options, from oral drug treatment to surgery. It is
recommended that treatment be tailored to the patient’s
needs, depending on symptom severity. Intra-articular
sodium hyaluronate is suggested for temporary sympto-
matic relief in cases where treatment with analgesics/
NSAIDs, acupuncture or physical therapy is inadequate,
and surgery is contraindicated or needs to be delayed.
This study has several limitations apart from the high
discontinuation rate. It was a preliminary study performed in
a relatively small number of patients, in the absence of
a comparator group and without blinding of either the patients
or investigators. It is therefore not possible to determine the
extent to which placebo effect might have contributed to the
study outcomes. A larger dataset with a control group is now
needed for robust characterization of the safety and efﬁcacy of
NASHA injection for treatment of GH-OA. Participants of the
present study were allowed to have bilateral GH-OA but were
only treated in one joint, and this could have reduced the
sensitivity with which responses to NASHAwere detectable.
Injections were performed without visual guidance; therefore,
it is possible that some treatments were not delivered to the
intra-articular space of the GH joint as intended. Strengths of
the study include the allowance of treatment only with acet-
aminophen apart from intra-articular NASHA, and the inclu-
sion of several different efﬁcacy variables.
Conclusions
In conclusion, this study provides preliminary evidence
that a single injection of NASHA may be efﬁcacious in
patients with symptomatic GH-OA. Improvements in pain
were clinically and statistically signiﬁcant and sustained
over the 6-month follow-up period, and the primary study
success criterion was met. NASHA appeared to be well
tolerated, and no new safety signals were identiﬁed.
Evidence from larger, controlled studies is needed to con-
ﬁrm these ﬁndings.
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